Pancytopenia （hemocytopenia） such as primary immune thrombocytopenia （ITP）, aplastic anemia and chronic neutropenia （agnogenic leukocytopenia） were often treated by glucocorticoids, androgen and immunosuppressiv...Pancytopenia （hemocytopenia） such as primary immune thrombocytopenia （ITP）, aplastic anemia and chronic neutropenia （agnogenic leukocytopenia） were often treated by glucocorticoids, androgen and immunosuppressive agents at present, but the response to these treatments has not been always satisfactory, and may cause serious adverse events. Our research has identified a biological active component in ginseng extract and the active component, panaxadiol saponins component （PDS-C）, was isolated from total saponins of ginsenosides, and formulated into capsules named as Painengda （派能达）. We successfully obtained approval from State Food and Drug Administration （SFDA） of China in 2010 to conduct clinical trials of PDS-C as class-five new Chinese patent medicine. Phase Ⅰand phase Ⅱ clinical trials of PDS-C and Painengda Capsule were carried out in the treatment of ITP and agnogenic leukocytopenia. Thecomposition and content of PDS-C have been analyzed and defined by high-performance liquid chromatography mass spectrometry （HPLC-MS） and HPLC using specific monomers of ginsenosides as the reference standards. PDS-C is very efficacious for treating mice and rats with ITP and aplastic anemia, and myelosuppression caused by chemotherapy or radiation. Our animal model studies and cell biology and molecular biology experiments demonstrated that PDS-C possessed dual activities, namely that of promoting proliferation and differentiation of hematopoietic progenitor cells, and that of regulating the immune function. PDS-C and Painengda Capsule as a new Chinese patent medicine have been successfully transferred to industry. We believe that PDS-C is effective and safe in the treatment of refractory hemocytopenia. The advantages are that it is effective in small doses, it is convenient to use because of its oral administration, its lack of adverse events, it could be used alone or in combination with pharmacological agents, which improve the efficacy and decrease adverse events.展开更多
目的观察重度妊娠高血压病（HCDP）对早产儿白细胞及凝血功能的影响。方法选取2011年1月至2014年12月收治的患有HCDP母亲所产的早产儿为观察组,对照组为健康母亲所产的早产儿。比较两组的血常规及凝血功能的特点、变化及影响因素,比较...目的观察重度妊娠高血压病（HCDP）对早产儿白细胞及凝血功能的影响。方法选取2011年1月至2014年12月收治的患有HCDP母亲所产的早产儿为观察组,对照组为健康母亲所产的早产儿。比较两组的血常规及凝血功能的特点、变化及影响因素,比较两组常见早产儿并发症的差异。结果观察组胎龄、出生体重小于对照组,SAG发生率高于对照组（P〈0.05）。观察组生后6 h、48~72 h、144 h 3个时间段内白细胞[白细胞总数（WBC）、中性粒细胞绝对数（ANC）]均低于对照组（P〈0.01）。观察组在生后6 h、48~72 h、144 h 3个时间段内的血小板（PLT）均低于对照组（P〈0.05）。观察组在生后6 h、48~72 h、144 h 3个时间段内的凝血功能：凝血酶原时间（PT）、部分活化凝血酶原时间（APTT）、血浆凝血酶时间（TT）均高于对照组（P〈0.05）;纤维蛋白原（FIB）低于对照组（P〈0.05）。两组间新生儿坏死性小肠结肠炎、呼吸窘迫综合征、支气管-肺发育不良（BPD）的发生率、病死率进行对比,差异无统计学意义（P〉0.05）;在观察组中,脑出血、肺出血、消化道出血、感染发生率高于对照组,差异有统计学意义（P〈0.05）。结论母亲患有重度HCDP,则所产的早产儿较健康母亲所产的早产儿更易发生白细胞、ANC、血小板减少及凝血功能障碍,并容易引起感染及合并出血。展开更多
基金Supported by the National Natural Science Foundation of China (No.30271597)Australia-China Institutional Links Research Program by International Development Program of Education Australia(No.IDP 2-8)+1 种基金Science and Technology Foundation of Zhjiang Province,China(No.2004C23002)Natural Science Foundation of Zhjiang Province,China(No.ZD0007)
文摘Pancytopenia （hemocytopenia） such as primary immune thrombocytopenia （ITP）, aplastic anemia and chronic neutropenia （agnogenic leukocytopenia） were often treated by glucocorticoids, androgen and immunosuppressive agents at present, but the response to these treatments has not been always satisfactory, and may cause serious adverse events. Our research has identified a biological active component in ginseng extract and the active component, panaxadiol saponins component （PDS-C）, was isolated from total saponins of ginsenosides, and formulated into capsules named as Painengda （派能达）. We successfully obtained approval from State Food and Drug Administration （SFDA） of China in 2010 to conduct clinical trials of PDS-C as class-five new Chinese patent medicine. Phase Ⅰand phase Ⅱ clinical trials of PDS-C and Painengda Capsule were carried out in the treatment of ITP and agnogenic leukocytopenia. Thecomposition and content of PDS-C have been analyzed and defined by high-performance liquid chromatography mass spectrometry （HPLC-MS） and HPLC using specific monomers of ginsenosides as the reference standards. PDS-C is very efficacious for treating mice and rats with ITP and aplastic anemia, and myelosuppression caused by chemotherapy or radiation. Our animal model studies and cell biology and molecular biology experiments demonstrated that PDS-C possessed dual activities, namely that of promoting proliferation and differentiation of hematopoietic progenitor cells, and that of regulating the immune function. PDS-C and Painengda Capsule as a new Chinese patent medicine have been successfully transferred to industry. We believe that PDS-C is effective and safe in the treatment of refractory hemocytopenia. The advantages are that it is effective in small doses, it is convenient to use because of its oral administration, its lack of adverse events, it could be used alone or in combination with pharmacological agents, which improve the efficacy and decrease adverse events.
文摘目的观察重度妊娠高血压病（HCDP）对早产儿白细胞及凝血功能的影响。方法选取2011年1月至2014年12月收治的患有HCDP母亲所产的早产儿为观察组,对照组为健康母亲所产的早产儿。比较两组的血常规及凝血功能的特点、变化及影响因素,比较两组常见早产儿并发症的差异。结果观察组胎龄、出生体重小于对照组,SAG发生率高于对照组（P〈0.05）。观察组生后6 h、48~72 h、144 h 3个时间段内白细胞[白细胞总数（WBC）、中性粒细胞绝对数（ANC）]均低于对照组（P〈0.01）。观察组在生后6 h、48~72 h、144 h 3个时间段内的血小板（PLT）均低于对照组（P〈0.05）。观察组在生后6 h、48~72 h、144 h 3个时间段内的凝血功能：凝血酶原时间（PT）、部分活化凝血酶原时间（APTT）、血浆凝血酶时间（TT）均高于对照组（P〈0.05）;纤维蛋白原（FIB）低于对照组（P〈0.05）。两组间新生儿坏死性小肠结肠炎、呼吸窘迫综合征、支气管-肺发育不良（BPD）的发生率、病死率进行对比,差异无统计学意义（P〉0.05）;在观察组中,脑出血、肺出血、消化道出血、感染发生率高于对照组,差异有统计学意义（P〈0.05）。结论母亲患有重度HCDP,则所产的早产儿较健康母亲所产的早产儿更易发生白细胞、ANC、血小板减少及凝血功能障碍,并容易引起感染及合并出血。
